These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29344878)

  • 1. Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
    Kanji ZS; Edwards AM; Mandelson MT; Sahar N; Lin BS; Badiozamani K; Song G; Alseidi A; Biehl TR; Kozarek RA; Helton WS; Picozzi VJ; Rocha FG
    Ann Surg Oncol; 2018 Apr; 25(4):1052-1060. PubMed ID: 29344878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
    Cho M; Wang-Gillam A; Myerson R; Gao F; Strasberg S; Picus J; Sorscher S; Fournier C; Nagaraj G; Parikh P; Suresh R; Linehan D; Tan BR
    HPB (Oxford); 2015 Jul; 17(7):587-93. PubMed ID: 25800066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
    Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
    Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG
    HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
    Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
    Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
    Habermehl D; Brecht IC; Bergmann F; Rieken S; Werner J; Büchler MW; Springfeld C; Jäger D; Debus J; Combs SE
    World J Surg Oncol; 2015 Apr; 13():149. PubMed ID: 25889749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
    Sherman WH; Hecht E; Leung D; Chu K
    Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
    Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
    Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
    Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
    Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
    Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
    Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
    Merrell KW; Haddock MG; Quevedo JF; Harmsen WS; Kendrick ML; Miller RC; Hallemeier CL
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):561-70. PubMed ID: 26867884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer.
    Liu Z; Luo G; Guo M; Jin K; Xiao Z; Liu L; Liu C; Xu J; Ni Q; Long J; Yu X
    Pancreatology; 2015; 15(3):253-8. PubMed ID: 25921232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
    McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R
    J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
    Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
    Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
    Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
    Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
    Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.